Summary
Synthetic oligopeptides were used to study the specificity of the interaction between heparin and platelet-derived growth factor (PDGF) in competition experiments. DNA synthesis in PDGF-dependent human arterial smooth muscle cell (hASMC) cultures was used as a biological tracer of PDGF activity. Oligo-108-124 (corresponding to amino acid residues 108-124 of the long PDGF A-chain isoform) had no effect on DNA synthesis in itself but competed at 10−10 M concentration effectively with PDGF for binding to heparin and released the block on thymidine incorporation induced by heparin. Poly-lysine-serine (lysine:serine ratio 3:1) was also effective but at a considerably higher concentration (10−6 M). Poly-arginine-serine did not compete with PDGF for heparin as deduced from the cell assay. This suggested that among basic amino acids, lysine was more important than arginine for heparin binding. Deletion of lysine residues 115 and 116 in Oligo-108-124 abolished its effect on the interaction between PDGF and heparin in the cell assay. Likewise, Oligo-69-84 (corresponding to the PDGF A-chain residues 69–84), with three lysine residues interrupted by a proline, was ineffective. In Oligo-108-124, the lysine residues are interrupted by an arginine. Our results suggested that the binding between PDGF and heparin is specific and that the amino acid sequence [-Lys115-Lys116-Arg117-Lys118-Arg119-] is of major importance. They do not however, exclude other domains of the PDGF A or B chains as additional binding sites for heparin nor do they exclude the possibility that heparin and the PDGF receptor share a common binding site.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Betsholtz, C.; Johnsson, A.; Heldin, C-H., et al. cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumour cell lines. Nature 320:695–699; 1986.
Bonthron, D. T.; Morton, C. C.; Orkin, S. H., et al. Platelet-derived growth factor A chain: gene structure, chromosomal location, and basis for alternative mRNA splicing. Proc. Natl. Acad. Sci. USA 85:1492–1496; 1988.
Cardin, A. D; Weintraub, H. J. R. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 9:21–32; 1989.
Castellot, J. J.; Addonizio, M. L.; Rosenberg, R., et al. Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle growth. J. Cell. Biol. 90:372–379; 1981.
Castellot, J. J.; Favreau, L. V.; Karnovsky, M. J., et al. Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin. Possible role of a platelet endoglycosidase. J. Biol. Chem. 257:11256–11260; 1982.
Clemmons, D. R. Interactions of circulating cell derived and plasma growth factors in stimulating cultured smooth muscle cell proliferation. J. Cell. Physiol. 121:425–430; 1984.
Clowes, A. W.; Karnovsky, M. J. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 265:625–626; 1977.
Dalferes, E. R.; Radhakrishnamurthy, B.; Ruiz, H. A., et al. Composition of proteoglycans from human atherosclerotic lesions. Exp. Mol. Pathol. 47:363–376; 1987.
Esch, F.; Baird, A.; Ling, N., et al. Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino terminal sequence of bovine brain acidic FGF. Proc. Natl. Acad. Sci. USA 85:6507–6511; 1985a.
Esch, F.; Ueno, N.; Baird, A., et al. Primary structure of bovine brain acidic fibroblast growth factor (FGF). Biochem. Biophys. Res. Commun. 133:554–562; 1985b.
Fager, G.; Hansson, G. K.; Ottosson, P., et al. Human arterial smooth muscle cells in culture. Effects of platelet-derived growth factor and heparin on growth in vitro. Exp. Cell Res. 176:319–335; 1988.
Fager, G.; Hansson, G. K.; Gown, A. M., et al. Human arterial smooth muscle cells in culture; inverse relationships between proliferation and expression of contractile proteins. In Vitro Cell. Dev. Biol. 25:511–519; 1989.
Fager, G.; Camejo, G.; Bonjers, G. Heparin-like glycosaminoglycans influence growth and phenotype of human arterial smooth muscle cells in vitro. I. Evidence for reversible binding and inactivating of the platelet-derived growth factor by heparin. In Vitro Cell. Dev. Biol. 28A:168–175; 1992.
Fritze, L. M.; Reilly, C. F.; Rosenberg, R. D. An antiproliferative heparan sulfate species produced by postconfluent smooth muscle cells. J. Cell. Biol. 100:1041–1049; 1985.
Greenfield, N.; Fasman, G. D. Computed circular dichroism spectra for the evaluation of protein conformation. Biochemistry 8:4108–4116; 1969.
Grotendorst, G. R.; Seppä, H. E. J.; Kleinman, H. K., et al. Attachment of smooth muscle cells to collagen and their migration toward platelet-derived growth factor. Proc. Natl. Acad. Sci. USA 78:3669–3672; 1981.
Grotendorst, G. R.; Chang, T.; Seppä, H. E. J., et al. Platelet-derived growth factor is a chemoattractant for vascular smooth muscle cells. J. Cell. Physiol. 113:261–266; 1982.
Hoover, R. L.; Rosenberg, R.; Haering, W., et al. Inhibition of rat arterial smooth muscle cell proliferation by heparin. Circ. Res. 47:578–583; 1980.
Johnson-Wint, B.; Hollis, S. A rapid in situ deoxyribonucleic acid assay for determining cell number in culture and tissue. Anal. Biochem. 122:338–344; 1982.
LaRochelle, W. J.; Giese, N.; May-Siroff, M., et al. Molecular localization of the transforming and secretory properties of PDGF A and PDGF B. Science 248:1541–1544; 1990.
Maher, D. W.; Lee, B. A.; Donoghue, D. J. The alternatively spliced exon of the platelet-derived growth factor A chain encodes a nuclear targeting signal. Mol. Cell. Biol. 9:2251–2253; 1989.
Majack, R. A.; Bornstein, P. Heparin and related glycosaminoglycans modulate the secretory phenotype of vascular smooth muscle cells. J. Cell. Biol. 99:1688–1695; 1984.
Majack, R. A.; Clowes, A. W. Inhibition of vascular smooth muscle cell migration by heparin-like glycosaminoglycans. J. Cell. Physiol. 118:253–256; 1984.
Majack, R. A.; Coates Cook, S.; Bornstein, P. Platelet-derived growth factor and heparin-like glycosaminoglycans regulate thrombospondin synthesis and deposition in the matrix by smooth muscle cells. J. Cell. Biol. 101:1059–1070; 1985.
Matoskova, B.; Rorsman, F.; Svensson, V., et al. Alternative splicing of the platelet-derived growth factor A-chain transcript occurs in normal as well as tumor cells and is conserved among mammalian species. Mol. Cell. Biol. 9:3148–3150; 1989.
Nilsson, J.; Ksiazek, T.; Thyberg, J., et al. Cell surface components and growth regulation in cultivated arterial smooth muscle cells. J. Cell. Sci. 64:107–121; 1983.
Östman, A.; Bäckström, G.; Fong, N., et al. Expression of three recombinant homodimeric isoforms of PDGF inSaccharomyces cerevisiae: evidence for difference in receptor binding and functional activities. Growth Factors 1:271–281; 1989.
Owens, G. K.; Loeb, A.; Gordon, D., et al. Expression of smooth muscle-specific isoactin in cultured vascular smooth muscle cells: relationship between growth and cytodifferentiation. J. Cell. Biol. 102:343–352; 1986.
Rorsman, F.; Bywater, M.; Knott, T. J., et al. Structural characterization of the human platelet-derived growth factor A-chain cDNA and gene: alternative exon usage predicts two different precursor proteins. Mol. Cell. Biol. 8:571–577; 1988.
Ross, R. Atherosclerosis: a problem of the biology of arterial wall cells and their interactions with blood components. Arteriosclerosis 1:293–311; 1981.
Seifert, R. A.; Schwartz, S. M.; Bowen-Pope, D. F. Developmentally regulated production of platelet-derived growth factor-like molecules. Nature 311:669–671; 1984.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fager, G., Camejo, G., Olsson, U. et al. Heparin-like glycosaminoglycans influence growth and phenotype of human arterial smooth muscle cells in vitro. II. The platelet-derived growth factor A-chain contains a sequence that specifically binds heparin. In Vitro Cell Dev Biol - Animal 28, 176–180 (1992). https://doi.org/10.1007/BF02631088
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02631088